Want to see FR:OSE full AI Analyst Report?
OSE Stock Chart & Stats
€3.16
€0.05(1.46%)
At close: 4:00 PM EDT
€3.16
€0.05(1.46%)
Day’s Range― - ―
52-Week Range€2.87 - €7.70
Previous CloseN/A
Volume102.94K
Average Volume (3M)154.47K
Market Cap
€75.71M
Enterprise Value€102.63M
Total Cash (Recent Filing)€22.65M
Total Debt (Recent Filing)€35.38M
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Sep 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.69
Shares Outstanding23,560,110
10 Day Avg. Volume172,695
30 Day Avg. Volume154,469
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)4.20
Price to Sales (P/S)43.87
P/FCF Ratio-3.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.2
Revenue Forecast (FY)€6.17M
Bulls Say, Bears Say
Bulls Say
Clinical-stage Immunotherapy PipelineOSE’s concentrated pipeline in immuno-oncology and immuno-inflammation targets enduring, large unmet needs and aligns with structural industry demand for immune-modulating therapies. This focused expertise supports sustained R&D relevance and partner interest over the next 2–6 months and beyond.
Partnering/licensing Business ModelA partnering/licensing model lets OSE monetize assets via upfronts, research funding and milestones without needing a commercial infrastructure. That model offers scalable, non-dilutive funding opportunities tied to pipeline progress and preserves capital if programs attract pharma partners.
Prior Strong Cash Generation From Milestone EventsThe 2024 cash inflow demonstrates OSE can generate substantial cash when clinical or partnership milestones are achieved. That historical ability to convert progress into material cash reduces structural funding risk if future milestones or collaborations recur.
Bears Say
Extreme Revenue And Earnings VolatilityA swing from strong revenue and profitability in 2024 to minimal revenue and deep losses in 2025 shows earnings quality is highly event-driven. Such volatility undermines predictability of cash flows and increases the likelihood of repeated financing needs over the next several quarters.
Meaningful Balance Sheet LeverageDebt exceeding equity indicates elevated financial leverage for a clinical-stage biotech with uncertain near-term revenues. This reduces flexibility to fund trials or pursue partnerships organically, and magnifies refinancing and covenant risk if losses persist.
Dependence On Milestone Timing And Small ScaleReliance on irregular collaboration payments and milestones makes revenue lumpy and unpredictable. Combined with a small 64-person team and recent -96% revenue growth, this increases execution risk and dependence on partners or capital markets to sustain programs over the medium term.
OSE Immunotherapeutics SA News
OSE FAQ
What was OSE Immunotherapeutics SA’s price range in the past 12 months?
OSE Immunotherapeutics SA lowest stock price was €2.87 and its highest was €7.70 in the past 12 months.
What is OSE Immunotherapeutics SA’s market cap?
OSE Immunotherapeutics SA’s market cap is €75.71M.
When is OSE Immunotherapeutics SA’s upcoming earnings report date?
OSE Immunotherapeutics SA’s upcoming earnings report date is Sep 28, 2026 which is in 58 days.
How were OSE Immunotherapeutics SA’s earnings last quarter?
OSE Immunotherapeutics SA released its earnings results on Apr 30, 2026. The company reported -€1.007 earnings per share for the quarter, missing the consensus estimate of N/A by -€1.007.
Is OSE Immunotherapeutics SA overvalued?
According to Wall Street analysts OSE Immunotherapeutics SA’s price is currently Overvalued.
Does OSE Immunotherapeutics SA pay dividends?
OSE Immunotherapeutics SA does not currently pay dividends.
What is OSE Immunotherapeutics SA’s EPS estimate?
OSE Immunotherapeutics SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OSE Immunotherapeutics SA have?
OSE Immunotherapeutics SA has 23,560,110 shares outstanding.
What happened to OSE Immunotherapeutics SA’s price movement after its last earnings report?
OSE Immunotherapeutics SA reported an EPS of -€1.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.288%.
Which hedge fund is a major shareholder of OSE Immunotherapeutics SA?
Currently, no hedge funds are holding shares in FR:OSE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
OSE Immunotherapeutics SA
Based in Nantes, France, OSE Immunotherapeutics S.A. specializes in creating immunotherapies designed to activate or regulate the immune system. Their work primarily targets both immuno-oncology and autoimmune diseases. Their advanced pipeline features Tedopi, which is currently in Phase III clinical trials for non-small cell lung cancer, with further Phase II investigations ongoing for pancreatic and ovarian cancers. For infectious diseases, they are developing CoVepiT, a prophylactic vaccine against the SARS-CoV-2 virus. In oncology, their portfolio also includes BI 765063, in Phase I for solid tumors, and BiCKI, an innovative bispecific checkpoint inhibitor platform. BiCKI is engineered to counteract cancer's primary and secondary resistance mechanisms by targeting PD-1 alongside other novel pathways. Addressing autoimmune and inflammatory conditions, OSE Immunotherapeutics is progressing OSE-127, a humanized monoclonal antibody in Phase II trials for both ulcerative colitis and Sjögren's Syndrome. FR104 is undergoing Phase I development for rheumatoid arthritis, while OSE-230, an agonist antibody against ChemR23, aims to resolve chronic inflammation. The company maintains strategic collaborations and partnerships with organizations such as GERCOR, Boehringer Ingelheim, Servier, and Chong Kun Dang Pharmaceutical Corporation. OSE Immunotherapeutics S.A. was formerly known as OSE Pharma SA until its name change in May 2016.